Literature DB >> 20665975

Diversity of emm sequence types in group A beta-haemolytic streptococci in two remote Northern Territory Indigenous communities: implications for vaccine development.

Leisha J Richardson1, Rebecca J Towers, Allen C Cheng, Bart J Currie, Jonathan R Carapetis, Phillip M Giffard, Malcolm I McDonald.   

Abstract

There is a high burden of disease due to group A streptococcus (GAS) in remote Northern Territory (NT) Indigenous communities. A proposed 26-valent GAS M-type vaccine covers 80-90% of pharyngeal and invasive isolates in the US. We examined the diversity and distribution of emm types in two remote Indigenous communities in the NT Top End over a 17-year period and compared them to the proposed vaccine types. Eighty emm types were identified between 1991 and 2007. Diversity in both communities was high (overall Simpson's index 0.976), but varied between communities. Prior to 2004, 71 emm types were identified and an additional 9 emm types were identified during a period of active surveillance in 2004-2005. The proposed 26-valent vaccine would be expected to cover only 20% of emm types recovered in this study. Of the 80 emm types, 16 (20%) were new sequence types identified since the last assignment of M types in 2002. The diversity of streptococcal isolates was higher than that reported from most industrialized countries, and similar to that described in several developing countries. A vaccine based on such a variable antigen is unlikely to provide effective protection in the highest risk populations. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665975     DOI: 10.1016/j.vaccine.2010.05.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Epidemiological and molecular analysis of Streptococcus pyogenes isolates causing invasive disease in Spain (1998-2009): comparison with non-invasive isolates.

Authors:  M Montes; C Ardanuy; E Tamayo; A Domènech; J Liñares; E Pérez-Trallero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

Review 2.  Current insights in invasive group A streptococcal infections in pediatrics.

Authors:  Anne Filleron; Eric Jeziorski; Anne-Laure Michon; Michel Rodière; Hélène Marchandin
Journal:  Eur J Pediatr       Date:  2012-02-25       Impact factor: 3.183

3.  Streptococcal pharyngitis in schoolchildren in Bamako, Mali.

Authors:  Milagritos D Tapia; Samba O Sow; Boubou Tamboura; Mahamadou M Keita; Abdoulaye Berthe; Mariam Samake; James P Nataro; Uma O Onwuchekwa; Thomas A Penfound; William Blackwelder; James B Dale; Karen L Kotloff
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

4.  Longitudinal Analysis of Group A Streptococcus emm Types and emm Clusters in a High-Prevalence Setting: Relationship between Past and Future Infections.

Authors:  Patricia Therese Campbell; Steven Y C Tong; Nicholas Geard; Mark R Davies; Kate A Worthing; Jake A Lacey; Pierre R Smeesters; Michael R Batzloff; Joseph Kado; Adam W J Jenney; Jodie Mcvernon; Andrew C Steer
Journal:  J Infect Dis       Date:  2020-04-07       Impact factor: 7.759

5.  High Incidence of Invasive Group A Streptococcal Infections in Remote Indigenous Communities in Northwestern Ontario, Canada.

Authors:  Natalie Bocking; Cai-Lei Matsumoto; Kassandra Loewen; Sarah Teatero; Alex Marchand-Austin; Janet Gordon; Nahuel Fittipaldi; Allison McGeer
Journal:  Open Forum Infect Dis       Date:  2016-12-07       Impact factor: 3.835

6.  Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease.

Authors:  Philip M Giffard; Steven Y C Tong; Deborah C Holt; Anna P Ralph; Bart J Currie
Journal:  PLoS Negl Trop Dis       Date:  2019-07-03

7.  Extensive diversity of Streptococcus pyogenes in a remote human population reflects global-scale transmission rather than localised diversification.

Authors:  Rebecca J Towers; Jonathan R Carapetis; Bart J Currie; Mark R Davies; Mark J Walker; Gordon Dougan; Philip M Giffard
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.